First Tracks Biotherapeutics, Inc. (TRAX) Stock Price & Analysis
First Tracks Biotherapeutics, Inc. (TRAX) closed at USD 36.04 on Thursday, October 15, 2026, up 5.60% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 34.13; the Oct 15, 2026 session ranged USD 33.99–36.3 on volume of 1,578,446 shares. Market capitalization is $1.29B, with a 52-week range of USD 14.72–49.91 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TRAX.md
Key facts (TRAX)
- Analysts: Buy (mean 1.75 on a 1–5 scale) (12 analysts), mean target USD 72.5 (range 57–100).
- Total return with dividends: 1Y +89.7% vs S&P 500 +18.1%; 5Y +53.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.89, revenue estimate $0K.
Analysts (TRAX)
Consensus Buy (mean 1.75 on a 1–5 scale), 12 analysts; mean target USD 72.5 (low 57, high 100).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Canaccord Genuity | Target raised | Buy | $50 → $60 |
| 2026-10-13 | Evercore ISI Group | Target raised | Outperform | $65 → $70 |
| 2026-10-13 | Wells Fargo | Target raised | Overweight | $62 → $70 |
| 2026-09-30 | Canaccord Genuity | Initiated | Buy | $50 |
| 2026-09-18 | Evercore ISI Group | Initiated | Outperform | $65 |
| 2026-09-16 | Guggenheim | Initiated | Buy | $100 |
| 2026-09-03 | HC Wainwright & Co. | Reiterated | Buy | $57 |
| 2026-08-13 | Barclays | Target raised | Overweight | $48 → $65 |
| 2026-08-13 | Wedbush | Target raised | Outperform | $60 → $70 |
| 2026-08-13 | Piper Sandler | Target raised | Overweight | $54 → $95 |
| 2026-08-13 | HC Wainwright & Co. | Target raised | Buy | $44 → $57 |
| 2026-08-10 | UBS | Target raised | Buy | $45 → $65 |
Total return (dividends reinvested) (TRAX)
| 1Y (from 2026-04-06) | 5Y (from 2026-04-06) | |
|---|---|---|
| Total return | +89.7% | +53.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 118.1% | 113.7% |
| Max drawdown | -39.7% (Apr 2026→Jun 2026) | -32.1% (Apr 2026→May 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 36.04 |
|---|---|
| Change | ▲ 5.60% (up) |
| Previous Close | USD 34.13 |
| Open | USD 34.26 |
| Day Range | USD 33.99 – 36.3 |
| 52-Week Range | USD 14.72 – 49.91 |
| Volume | 1,578,446 shares |
| Market Cap | $1.29B |
| Exchange | NMS |
Technical Analysis (TRAX)
Nexqual's technical model rates TRAX "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.48 (neutral) |
| vs SMA50 | Below (USD 39.47) |
| MACD | -1.55 (negative) |
Analyst Ratings (TRAX)
Wall Street analysts rate TRAX "Buy" based on 12 analysts, with a mean price target of USD 72.5 (range USD 57–100), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 72.5 |
| High Target | USD 100 |
| Low Target | USD 57 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (TRAX)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.89 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.95 vs est -0.8 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (TRAX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.03 |
| Current Ratio | 14.28 |
| Total Cash | $168.02M |
| Total Debt | $4.33M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (TRAX)
Nexqual rates First Tracks Biotherapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $168M cash vs $4M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$124M (TTM) |
| Efficiency | Mixed — No data |
Ownership (TRAX)
| Insider Ownership | +8.75% |
|---|---|
| Institutional Ownership | +100.79% |
| Shares Outstanding | 35.73M |
| Float | 26.15M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (TRAX)
First Tracks Biotherapeutics, Inc. is led by Daniel R. Faga (age 45), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO, President & Director | Daniel R. Faga (age 45) |
|---|---|
| Chief Financial Officer | Ajim A. Tamboli C.F.A. (age 48) |
Major Backers & Investors (TRAX)
Notable institutional backers of First Tracks Biotherapeutics, Inc. include EcoR1 Capital, LLC, TCG Crossover Management, LLC, FMR, LLC, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| EcoR1 Capital, LLC | 8.88% |
| TCG Crossover Management, LLC | 8.1% |
| FMR, LLC | 5.75% |
| Affinity Asset Advisors, Llc | 5.69% |
| Trails Edge Capital Partners, LP | 4.24% |
| Jupiter Topco LLC | 3.05% |
| Fidelity | 3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.04% |
| BlackRock | 7.18% |
| State Street | 6.68% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt